Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01545050 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
A Phase 2 study, sponsored by CSL Behring.
- Terminated
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT01545050 is a Phase 2 study that was terminated before completion, run by CSL Behring. The registered enrollment target is 72 participants.
The verdict
NCT01545050, a Phase 2 study, was terminated before completion, sponsored by CSL Behring.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with moderate to severe Crohn's disease and who have had an insufficient response to conventional therapy or have failed Anti-Tumor Necrosis Factor (anti-TNF) therapy.
Interventions
- BIOLOGICAL BMS-945429
- BIOLOGICAL Placebo matching with BMS-945429
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01545050
The ClinicalTrials.gov registry entry for NCT01545050 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-945429 is the first listed.
NCT01545050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01545050 about?
NCT01545050 is a clinical study titled "Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease". The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with moderate to severe Crohn's disease and who have had an insufficient response to conventional therapy or have failed Anti-Tumor Necrosis Factor (anti-TNF) therapy.
What is the current status of trial NCT01545050?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2012-06. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01545050?
The interventions under investigation include: BMS-945429 (BIOLOGICAL), Placebo matching with BMS-945429 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01545050?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.